A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs MCS 110 (Primary) ; Spartalizumab (Primary)
- Indications Breast cancer; Endometrial cancer; Malignant melanoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Feb 2018 Planned End Date changed from 17 Jun 2019 to 15 May 2019.
- 21 Feb 2018 Planned primary completion date changed from 29 Jul 2018 to 15 May 2019.
- 03 Nov 2017 Planned number of patients changed from 196 to 175.